Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial.
Klaus Friedrich RabeFernando J MartinezDave SinghRoopa TrivediMartin JenkinsPatrick DarkenMagnus AurivilliusPaul DorinskyPublished in: Therapeutic advances in respiratory disease (2022)
BGF 320/18/9.6 µg and 160/18/9.6 µg significantly improved trough FEV1versus GFF and FEV1 AUC0-4versus BFF at week 24. The lung function benefits with both doses of BGF were maintained following 52 weeks of treatment.The reviews of this paper are available via the supplemental material section.